FORUS Therapeutics Inc and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for XPOVIO(R)(selinexor)
- Written by Newsfile
- The pCPA agreement will support the public listings and reimbursement of XPOVIO.
- XPOVIO represents the first new drug class for the treatment of early relapsed or refractory multiple myeloma introduced into Canada within the last 7 years.
- XPOVIO, a Selective Inhibitor of the Nuclear Export (SINE) protein XPO1, offers myeloma treaters and...